About this episode
Justin Hanka is the Co-Founder and Chief Executive Director of MindBio Therapeutics, world leaders in microdosing of psychedelics,
Justin joins the Mycopreneur Podcast from his home in Melbourne, Australia to discuss the rigorous scientific inquiry and data collection that MindBio therapeutics is conducting in Phase 2 clinical trials assessing the medical efficacy of microdosing LSD to treat Major Depressive Disorder.
We discuss the process of clinical trials, the data collected from MindBio Therapeutics Phase 1 clinical trials, what regulators need in order to approve psychedelics as a treatment model for Major Depressive Disorder, and the toppling data that is eradicating lingering stigma against psychedelic medicines in the medical establishment and society at large.
Please consider rating, reviewing, and sharing the podcast wherever you're listening.
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time Mycopreneur publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Mycopreneur
Lee Carroll: Ergothioneine in Support of Psychedelic Therapy
Mycopreneur
Adam Miezio: Psychedelics in the Epstein Files
Mycopreneur
Robert Gallery: Ibogaine For Athletes with Traumatic Brain Injuries
Mycopreneur
Melanie Tremblay: The Hidden Dangers of AI-Generated Mushroom Claims
Mycopreneur